Tumor Organoids Improve Mutation Detection of Pancreatic Ductal Adenocarcinoma
This project investigated whether patient-derived organoids (PDOs) can enhance the accurate identification of somatic mutation and tumor-specific neoantigens in PDAC, which generally present with low tumor cellularity.  Surgically resected PDAC tumors and their paired PDOs from 21 patients were examined. Whole-exome sequencing (WES) of tumor tissue, organoids, and peripheral blood mononuclear cells was performed to identify somatic mutations.